Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Randomized, double-blind, split-side, comparison study of moisturizer containing licochalcone a and 1% hydrocortisone in the treatment of childhood atopic dermatitis
Authors: Siriwan Wananukul
Susheera Chatproedprai
Amornsri Chunharas
Wanida Limpongsanuruk
Srisupalak Singalavanija
Rattanawalai Nitiyarom
Wanee Wisuthsarewong
Chulalongkorn University
Mahidol University
Rangsit University
Keywords: Medicine
Issue Date: 1-Sep-2013
Citation: Journal of the Medical Association of Thailand. Vol.96, No.9 (2013), 1135-1142
Abstract: Background: Atopic dermatitis (AD) is a common chronic inflammatory skin lesion in children. Topical corticosteroid is the mainstay of treatment. Objective: To compare the efficacy of moisturizer containing licochalcone A (Lic A) and 1% hydrocortisone for the treatment of mild to moderate childhood AD. Material and Method: This was a multicenter, randomized, prospective, split-side, double-blind study in 55 children between the age of three months and 14 years. Patients with AD were treated twice daily, simultaneously with either Lic A or 1% hydrocortisone on opposite sides of the lesion. The SCORAD and transepidermal water loss (TEWL) were performed at the baseline, 2-week, and 4-week visits. Lic A was used on both sides of the body for another four weeks to see the effects and TEWL. Results: In a randomized period, both products were equally effective in the treatment. SCORAD decreased significantly from baseline for both treatments throughout the first four weeks (p<0.001). There was no statistically significant difference in SCORAD between both treatments (p = 0.321 and p = 0.146 at week 2 and 4, respectively). Lic A had statistically significant decrease in TEWL (p = 0.027 and p = 0.03 at weeks 2 and 4, respectively). One patient had infection on skin lesions of both sides of the body. Forty-three patients continued to the period of using Lic A on both sides of the body. SCORAD and TEWL were comparable to the end of the randomized period and significantly lower from baseline (p<0.001). Skin lesions flared up in three patients (7.5%). Conclusion: Lic A had a similar result in terms of SCORAD compared to 1% hydrocortisone for the treatment of mild and moderate AD. TEWL was significantly lower than baseline on the side that used Lic A. Continuing use of Lic A for four weeks can maintain clinical and barrier improvement.
ISSN: 01252208
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.